MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds
Previous
Next

thought leadership

Integrated evidence generation 2.0: A strategy for every stakeholder

Sarah Feaver, Senior Director, Scientific Strategy; Andrée Rose, Senior Director, Scientific Strategy; and Samara Ferguson, Executive Director, Market Access | 9/26/2023

What do you consider a successful outcome for your evidence‑generation plan? If your answer is “regulatory approval,” then you may be falling behind. Here, our market access and medical experts reveal why innovative biopharmaceutical companies are thinking beyond the regulators to take a holistic approach to evidence generation that meets the needs of a variety of stakeholders.

The advent of biologic therapies in the 1970s along with the decoding of the human genome in 2003 heralded an explosion in pharmaceutical innovation. These groundbreaking discoveries ushered in a new age of precision and personalized medicine, leading to innovations in novel targeted proteins, cell and gene therapies, and medical devices, which are often accompanied by bespoke diagnostic and testing criteria.

However, such advancements, while transforming patients’ lives, are fueling an increasingly complex market landscape characterized by smaller and harder‑to‑reach patient populations, complicated diagnostic processes, and significant and fragmented pockets of high unmet need. Future advances in personalized medicine, harnessing the power of big data, artificial intelligence, machine learning, and personal digital technology to deliver truly bespoke and personalized solutions for improving patient outcomes are likely to shake the market further.

To meet patients’ needs for effective therapies, regulatory bodies have begun accepting evidence beyond large, randomized, controlled clinical trials and have developed novel pathways to accelerate approval. This has led to an increase in products coming to market with single‑arm Phase 3 data and surrogate endpoints or Phase 2b data, with planned confirmatory data to be released in the future. As a result, payers face high levels of uncertainty when determining the relative efficacy and cost‑effectiveness of the product. Additionally, new forms of data, such as real‑world evidence (RWE), are becoming more readily accepted for demonstrating the long‑term value of novel medicines.

The evidence‑generation process has become far more challenging. The combination of high science and the nuances of the evolving landscape has led to greater evidence gaps for a growing number of stakeholders—from payers and regulators to patients and healthcare professionals—each of whom requires a more detailed understanding of the scientific data and relative benefits compared with the current standard of care and other novel therapies to help them make decisions.

Drug developers need to take an innovative and agile approach to evidence generation to meet the needs of stakeholders holistically, if they are to achieve their vision and ensure novel therapies are maximizing their potential to deliver patient benefit and value to society.

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Avalere Health website, such as the pages you visit.

For more information, check the cookie statement

32E8261E-A569-4B66-ACC6-3CB772DDEDEE

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on avalerehealth.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Avalerehealth.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.